Medtronic Announces Intent To Spin Diabetes Business

Medtronic (MDT) announced plans to spin off its Diabetes business into a new standalone entity via a capital markets transaction, likely an IPO followed by a split-off, expected to be completed within 18 months. The move aims to sharpen Medtronic's focus on higher-growth, higher-margin segments like Cardiovascular and Neuroscience, which account for over 90% of revenue, while enabling the New Diabetes Company to pursue focused innovation in insulin management; the transaction is projected to be accretive to Medtronic’s gross and operating margins and EPS. Despite recent growth in the Diabetes segment, its historical underperformance and increasing competition prompted the strategic shift, with Medtronic anticipating an increase of approximately 50 and 100 basis points to its gross and adjusted operating margins, respectively.

Analysis

Medtronic plc has announced its intention to spin off its Diabetes business into a standalone entity, New Diabetes Company, within 18 months, primarily via an IPO followed by a split-off. This strategic separation aims to allow Medtronic (RemainCo) to concentrate on its higher-margin and faster-growing core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies, which constitute over 90.0% of its total revenues. The Diabetes segment, contributing approximately $2.5 billion or 8.0% of Medtronic's $32.4 billion revenue in FY25 (as per deal rationale figures), has underperformed, with a ~1.4% revenue CAGR over the past five years compared to Medtronic's overall ~2.9%. Its operating margin also declined from 30.9% in FY19 to 15.8% in FY25, burdened by FDA regulatory setbacks, intense competition from rivals like Dexcom and Abbott, and shifting treatment paradigms due to GLP-1 agonists. Despite a recent 10.7% YoY revenue growth in the Diabetes segment for FY25 (reaching $2.7 billion out of $33.5 billion total MDT revenue) and six quarters of double-digit growth, Medtronic views the spin-off as crucial for improving its financial profile. The transaction is expected to be accretive to Medtronic's gross margin by approximately 50 basis points, adjusted operating margins by around 100 basis points, and earnings per share, while maintaining its current dividend policy. The New Diabetes Company will focus on intensive insulin management, leveraging its portfolio of insulin pumps, CGMs, and digital solutions, with Que Dallara as CEO. Medtronic's Q4FY25 results showed overall revenue growth of 3.9% YoY to $8.9 billion, and FY25 revenue grew 3.6% to $33.5 billion, with adjusted diluted EPS at $1.62 for Q4 and $5.49 for FY25, beating consensus estimates.

Key Decisions for Investors

• Investors should evaluate Medtronic (RemainCo) based on its potential for enhanced margin expansion, EPS accretion, and a sharpened focus on its core high-growth MedTech segments post-separation.
• Monitor the execution of the spin-off, including regulatory approvals and capital market conditions for the New Diabetes Company's IPO, as these will be critical for timely value realization.
• Assess the New Diabetes Company as a distinct investment opportunity once it becomes publicly traded, considering its dedicated focus on the diabetes market against its historical challenges and the competitive landscape.
• Consider the strategic implications of this portfolio restructuring, as it aims to unlock shareholder value by separating a historically underperforming, albeit recently improving, business unit.